Scarica l'app Stockscreener
13.28
0.12%
-0.015
Precedente Chiudi:
$13.29
Aprire:
$13.28
Volume 24 ore:
668.96K
Relative Volume:
0.40
Capitalizzazione di mercato:
$42.13B
Reddito:
$30.27B
Utile/perdita netta:
$1.93B
Rapporto P/E:
29.90
EPS:
0.444
Flusso di cassa netto:
$3.45B
1 W Prestazione:
-2.18%
1M Prestazione:
-6.19%
6M Prestazione:
+0.56%
1 anno Prestazione:
-5.32%
Intervallo 1D:
$13.27
$13.35
Intervallo di 1 settimana:
$13.21
$13.68
Portata 52W:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Confronta TAK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| TAK | 13.27 | 42.13B | 30.27B | 1.93B | 3.45B | 0.444 |
| ZTS | 176.24 | 78.47B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.53 | 42.84B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 17.03 | 19.19B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.23 | 15.67B | 15.24B | -646.50M | 1.88B | 1.53 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Weekly Upgrades and Downgrades - InvestorPlace
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily
Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily
Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily
Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News
North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily
AHH stock rated a Buy by Stifel - Knox Daily
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily
Brookline Bancorp, Inc. [BRKL] Records 50-Day SMA of $10.01 - Knox Daily
Crescent Energy Co. [CRGY] Records 200-Day SMA of $11.56 - Knox Daily
Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily
TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Ipsen provides update on CONTACT-02 Phase III trial in - GlobeNewswire
Biotech Soars, And Then Dives, On $5 Billion Opportunity - Investor's Business Daily
France Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):